Literature DB >> 22779406

Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.

Tolga Sutlu1, Sanna Nyström, Mari Gilljam, Birgitta Stellan, Steven E Applequist, Evren Alici.   

Abstract

Adoptive immunotherapy with genetically modified natural killer (NK) cells is a promising approach for cancer treatment. Yet, optimization of highly efficient and clinically applicable gene transfer protocols for NK cells still presents a challenge. In this study, we aimed at identifying conditions under which optimum lentiviral gene transfer to NK cells can be achieved. Our results demonstrate that stimulation of NK cells with interleukin (IL)-2 and IL-21 supports efficient transduction using a VSV-G pseudotyped lentiviral vector. Moreover, we have identified that inhibition of innate immune receptor signaling greatly enhances transduction efficiency. We were able to boost the efficiency of lentiviral genetic modification on average 3.8-fold using BX795, an inhibitor of the TBK1/IKKɛ complex acting downstream of RIG-I, MDA-5, and TLR3. We have also observed that the use of BX795 enhances lentiviral transduction efficiency in a number of human and mouse cell lines, indicating a broadly applicable, practical, and safe approach that has the potential of being applicable to various gene therapy protocols.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22779406      PMCID: PMC3472531          DOI: 10.1089/hum.2012.080

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  54 in total

1.  Rapid and highly efficient gene transfer into natural killer cells by nucleofection.

Authors:  Hans-Ingo Trompeter; Sandra Weinhold; Corinna Thiel; Peter Wernet; Markus Uhrberg
Journal:  J Immunol Methods       Date:  2003-03-01       Impact factor: 2.303

2.  Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors.

Authors:  Roland Schroers; York Hildebrandt; Justin Hasenkamp; Bertram Glass; André Lieber; Gerald Wulf; Matthias Piesche
Journal:  Exp Hematol       Date:  2004-06       Impact factor: 3.084

3.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

Authors:  S Worgall; G Wolff; E Falck-Pedersen; R G Crystal
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

4.  Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors.

Authors:  E Costello; M Munoz; E Buetti; P R Meylan; H Diggelmann; M Thali
Journal:  Gene Ther       Date:  2000-04       Impact factor: 5.250

5.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS.

Authors:  John A Olschowka; William J Bowers; Sean D Hurley; Michael A Mastrangelo; Howard J Federoff
Journal:  Mol Ther       Date:  2003-02       Impact factor: 11.454

7.  Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

Authors:  Christoph Uherek; Torsten Tonn; Barbara Uherek; Sven Becker; Barbara Schnierle; Hans-Georg Klingemann; Winfried Wels
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Interleukin-21 activates human natural killer cells and modulates their surface receptor expression.

Authors:  Kresten Skak; Klaus Stensgaard Frederiksen; Dorthe Lundsgaard
Journal:  Immunology       Date:  2007-11-14       Impact factor: 7.397

Review 9.  Molecular basis of the inflammatory response to adenovirus vectors.

Authors:  Q Liu; D A Muruve
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

10.  Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy.

Authors:  Jian Zhang; Rui Sun; Haiming Wei; Jianhua Zhang; Zhigang Tian
Journal:  Haematologica       Date:  2004-03       Impact factor: 9.941

View more
  58 in total

1.  EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.

Authors:  Chuanlong Zhu; Fei Xiao; Jian Hong; Kun Wang; Xiao Liu; Dachuan Cai; Dahlene N Fusco; Lei Zhao; Soung Won Jeong; Cynthia Brisac; Pattranuch Chusri; Esperance A Schaefer; Hong Zhao; Lee F Peng; Wenyu Lin; Raymond T Chung
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 2.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

3.  CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.

Authors:  Shi Yong Neo; Ying Yang; Julien Record; Ran Ma; Xinsong Chen; Ziqing Chen; Nicholas P Tobin; Emily Blake; Christina Seitz; Ron Thomas; Arnika Kathleen Wagner; John Andersson; Jana de Boniface; Jonas Bergh; Shannon Murray; Evren Alici; Richard Childs; Martin Johansson; Lisa S Westerberg; Felix Haglund; Johan Hartman; Andreas Lundqvist
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells.

Authors:  Arash Nanbakhsh; Brad Best; Matthew Riese; Sridhar Rao; Li Wang; Jeffrey Medin; Monica S Thakar; Subramaniam Malarkannan
Journal:  J Vis Exp       Date:  2018-01-15       Impact factor: 1.355

5.  Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy.

Authors:  Aaron J Wilk; Nancy Lynn-Benner Weidenbacher; Rosemary Vergara; Ole A W Haabeth; Ronald Levy; Robert M Waymouth; Paul A Wender; Catherine A Blish
Journal:  Blood Adv       Date:  2020-09-08

6.  Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.

Authors:  C Quintarelli; S Sivori; S Caruso; S Carlomagno; L Moretta; F Locatelli; M Falco; I Boffa; D Orlando; M Guercio; Z Abbaszadeh; M Sinibaldi; S Di Cecca; A Camera; B Cembrola; A Pitisci; M Andreani; L Vinti; S Gattari; F Del Bufalo; M Algeri; G Li Pira; A Moseley; B De Angelis
Journal:  Leukemia       Date:  2019-11-19       Impact factor: 11.528

7.  Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.

Authors:  Meisam Naeimi Kararoudi; Hamid Dolatshad; Prashant Trikha; Syed-Rehan A Hussain; Ezgi Elmas; Jennifer A Foltz; Jena E Moseman; Aarohi Thakkar; Robin J Nakkula; Margaret Lamb; Nitin Chakravarti; K John McLaughlin; Dean A Lee
Journal:  J Vis Exp       Date:  2018-06-14       Impact factor: 1.355

Review 8.  Bringing natural killer cells to the clinic: ex vivo manipulation.

Authors:  Richard W Childs; Maria Berg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

9.  Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Authors:  Kurt Schönfeld; Christiane Sahm; Congcong Zhang; Sonja Naundorf; Christian Brendel; Marcus Odendahl; Paulina Nowakowska; Halvard Bönig; Ulrike Köhl; Stephan Kloess; Sylvia Köhler; Heidi Holtgreve-Grez; Anna Jauch; Manfred Schmidt; Ralf Schubert; Klaus Kühlcke; Erhard Seifried; Hans G Klingemann; Michael A Rieger; Torsten Tonn; Manuel Grez; Winfried S Wels
Journal:  Mol Ther       Date:  2014-11-06       Impact factor: 11.454

10.  TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis.

Authors:  Sanna Nyström; Daniel J Antoine; Peter Lundbäck; John G Lock; Andreia F Nita; Kari Högstrand; Alf Grandien; Helena Erlandsson-Harris; Ulf Andersson; Steven E Applequist
Journal:  EMBO J       Date:  2012-12-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.